Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: infliximab

Comparative Assessment of the Different ACR/EULAR Remission Definitions for RA for Their Use as Clinical Trial End Points

Arthritis & Rheumatology  |  

Significant advances have been made in the treatment of RA over the past 20 years, and with the hope of developing even more effective therapeutics, achieving a very low level of disease activity, such as remission, is an important outcome to be examined. The ACR and EULAR have defined remission using Boolean- or index-based criteria. The researchers undertook this study to compare definitions of remission to inform choice of end points for future RA clinical trials and included in their comparison the remission criterion of a score of ≤2.8 on the Clinical Disease Activity Index…

Anti-Interleukin-6 Therapy for Erdheim-Chester Disease Warrants Study

Stefanie D. Wade, MD, Michael A. Seidman, MD, Edward C. Jones, MD, Arnold Radu, MD, Ryan Paterson, MD, Vikram Deshpande, MD, John H. Stone, MD, & Mollie N. Carruthers, MD  |  

Erdheim-Chester disease (ECD) is a rare, non-Langerhan’s cell histiocytosis characterized by tissue infiltration of CD68-positive and CD1a-negative foamy histiocytes.1 ECD was discovered as a lipid granulomatosis in 1930 by Jakob Erdheim and his pupil, William Chester, and approximately 500 cases have been described to date.1 ECD has a heterogeneous course and prognosis ranging from an…

Biosimilars to Raise Unique Questions

  |  

Rheumatologists are accustomed to educating patients about medications, but biologic medications—and now biosimilars—require some additional time and discussion. “Biologics are inherently more complex [than other medications], and there are multiple issues to consider before initiating treatment,” says K. “Kwas” Huston, MD, The Center for Rheumatic Disease, Kansas City, Mo. The first FDA-approved biosimilar to become…

Pediatric Rheumatology Research Highlights Successful Approaches to Manage Juvenile Rheumatic Diseases

  |  

WASHINGTON, D.C.—Patients with juvenile rheumatic diseases are thriving in an era of highly effective therapies, successful self-management strategies, better understanding of genetic links to autoimmunity risk and improved efforts to listen to and engage with these young patients. That bright picture for young people with arthritis was presented by pediatrics at the ACR/ARHP Concurrent Abstract…

Tips for Diagnosing, Treating Seldom Seen Forms of Vasculitis

  |  

WASHINGTON, D.C.—The vast majority of the attention given to vasculitis at the ACR/ARHP Annual Meeting, year after year, focuses on ANCA-associated vasculitis and large-vessel vasculitis, said Philip Seo, MD, MHS, director of the Johns Hopkins Vasculitis Center and moderator of the 2016 ACR Review Course titled, Neglected Vasculitis. That leaves out a lot. “These are…

Syda Productions/shutterstock.com

Tips, Resources to Help Rheumatologists Educate Patients on Biologics and Biosimilars

  |  

Rheumatologists are accustomed to educating patients about medications—but biologic medications require some additional time and discussion. “Biologics are inherently more complex [than other medications], and there are multiple issues to consider before initiating treatment,” says K. “Kwas” Huston, MD, The Center for Rheumatic Disease, Kansas City, Mo. “This includes the patient’s disease activity, prior medications…

Biosimilar Update: ACR Says FDA Draft Guidance Is Promising & Biosimilar to Humira (Adalimumab) Enters Regulatory Review

  |  

The ACR has released a statement, responding positively to the release of the latest U.S. Food and Drug Administration (FDA) draft guidance on biosimilar drug development. Also, BI 695501, a biosimilar to Humira (adalimumab) made by Boehringer Ingelheim, has been accepted for regulatory review in both the U.S. and Europe. ACR Responds to FDA Biosimilar…

Rheumatology Coding Question: Deconstructing Evaluation and Management Codes

  |  

A 50-year-old male patient returns to the office for a follow-up visit for a diagnosis of generalized primary osteoarthritis of multiple sites. The patient tells the medical assistant that he is experiencing sharp throbbing pain in his left hip and right and left knees. He states the pain level is 6 out of 10 and…